---
reference_id: "PMID:37827216"
title: Cell Plasticity in a Mouse Model of Benign Prostate Hyperplasia Drives Amplification of Androgen-Independent Epithelial Cell Populations Sensitive to Antioxidant Therapy.
authors:
- Dos Santos L
- Carbone F
- Pacreau E
- Diarra S
- Luka M
- Pigat N
- Baures M
- Navarro E
- Anract J
- Barry Delongchamps N
- Cagnard N
- Bost F
- Nemazanyy I
- Petitjean O
- Hamaï A
- Ménager M
- Palea S
- Guidotti JE
- Goffin V
journal: Am J Pathol
year: '2024'
doi: 10.1016/j.ajpath.2023.09.010
content_type: abstract_only
---

# Cell Plasticity in a Mouse Model of Benign Prostate Hyperplasia Drives Amplification of Androgen-Independent Epithelial Cell Populations Sensitive to Antioxidant Therapy.
**Authors:** Dos Santos L, Carbone F, Pacreau E, Diarra S, Luka M, Pigat N, Baures M, Navarro E, Anract J, Barry Delongchamps N, Cagnard N, Bost F, Nemazanyy I, Petitjean O, Hamaï A, Ménager M, Palea S, Guidotti JE, Goffin V
**Journal:** Am J Pathol (2024)
**DOI:** [10.1016/j.ajpath.2023.09.010](https://doi.org/10.1016/j.ajpath.2023.09.010)

## Content

1. Am J Pathol. 2024 Jan;194(1):30-51. doi: 10.1016/j.ajpath.2023.09.010. Epub
2023  Oct 10.

Cell Plasticity in a Mouse Model of Benign Prostate Hyperplasia Drives 
Amplification of Androgen-Independent Epithelial Cell Populations Sensitive to 
Antioxidant Therapy.

Dos Santos L(1), Carbone F(2), Pacreau E(1), Diarra S(3), Luka M(4), Pigat N(1), 
Baures M(1), Navarro E(1), Anract J(5), Barry Delongchamps N(5), Cagnard N(6), 
Bost F(7), Nemazanyy I(8), Petitjean O(9), Hamaï A(1), Ménager M(2), Palea S(3), 
Guidotti JE(1), Goffin V(10).

Author information:
(1)Institut Necker Enfants Malades, Université Paris Cité, INSERM UMR-S1151, 
CNRS UMR-S8253, Paris, France.
(2)Laboratory of Inflammatory Responses and Transcriptomic Networks in Diseases, 
Imagine Institute, Université Paris Cité, Atip-Avenir Team, INSERM UMR 1163, 
Paris, France; Labtech Single-Cell@Imagine, Imagine Institute, INSERM UMR 1163, 
Paris, France.
(3)Humana Biosciences SAS, Prologue Biotech, Labège, France.
(4)Institut Necker Enfants Malades, Université Paris Cité, INSERM UMR-S1151, 
CNRS UMR-S8253, Paris, France; Laboratory of Inflammatory Responses and 
Transcriptomic Networks in Diseases, Imagine Institute, Université Paris Cité, 
Atip-Avenir Team, INSERM UMR 1163, Paris, France.
(5)Institut Necker Enfants Malades, Université Paris Cité, INSERM UMR-S1151, 
CNRS UMR-S8253, Paris, France; Urology Department, Hôpital Cochin, Assistance 
Publique Hôpitaux de Paris, Paris, France.
(6)Bioinformatics Core Platform, Université Paris Cité, Structure Fédérative de 
Recherche Necker, INSERM US24/CNRS UAR3633, Paris, France.
(7)C3M, INSERM U1065, Université Côte d'Azur, Equipe Labélisée Ligue Nationale 
contre le Cancer, Nice, France.
(8)Metabolomics Core Facility, Université de Paris-Structure Fédérative de 
Recherche Necker, INSERM US24/CNRS UAR3633, Paris, France.
(9)Zion Pharma, Marseille, France.
(10)Institut Necker Enfants Malades, Université Paris Cité, INSERM UMR-S1151, 
CNRS UMR-S8253, Paris, France. Electronic address: vincent.goffin@inserm.fr.

Benign prostate hyperplasia (BPH) is caused by the nonmalignant enlargement of 
the transition zone of the prostate gland, leading to lower urinary tract 
symptoms. Although current medical treatments are unsatisfactory in many 
patients, the limited understanding of the mechanisms driving disease 
progression prevents the development of alternative therapeutic strategies. The 
probasin-prolactin (Pb-PRL) transgenic mouse recapitulates many 
histopathological features of human BPH. Herein, these alterations parallel 
urodynamic disturbance reminiscent of lower urinary tract symptoms. Single-cell 
RNA-sequencing analysis of Pb-PRL mouse prostates revealed that their epithelium 
mainly includes low-androgen signaling cell populations analogous to 
Club/Hillock cells enriched in the aged human prostate. These intermediate cells 
are predicted to result from the reprogramming of androgen-dependent luminal 
cells. Pb-PRL mouse prostates exhibited increased vulnerability to oxidative 
stress due to reduction of antioxidant enzyme expression. One-month treatment of 
Pb-PRL mice with anethole trithione (ATT), a specific inhibitor of mitochondrial 
ROS production, reduced prostate weight and voiding frequency. In human BPH-1 
epithelial cells, ATT decreased mitochondrial metabolism, cell proliferation, 
and stemness features. ATT prevented the growth of organoids generated by sorted 
Pb-PRL basal and LSCmed cells, the two major BPH-associated, 
androgen-independent epithelial cell compartments. Taken together, these results 
support cell plasticity as a driver of BPH progression and therapeutic 
resistance to androgen signaling inhibition, and identify antioxidant therapy as 
a promising treatment of BPH.

Copyright © 2024 American Society for Investigative Pathology. Published by 
Elsevier Inc. All rights reserved.

DOI: 10.1016/j.ajpath.2023.09.010
PMID: 37827216 [Indexed for MEDLINE]

Conflict of interest statement: Disclosure Statement O.P. holds a patent on ATT 
repositioning for BPH treatment. He participated in initial study design, but 
had no role in data collection, analysis, and interpretation, or writing of the 
manuscript.